Editas Medicine (EDIT) Income from Continuing Operations (2015 - 2025)
Editas Medicine (EDIT) posted quarterly Income from Continuing Operations of 25116000.0 for Q3 2025, up 59.58% year-over-year from 15738914.2 in Q3 2024, and up 51.66% quarter-over-quarter from 51962000.0 in Q2 2025.
Powered by 
Analysis
Editas Medicine (EDIT) Income from Continuing Operations (2015 - 2025) Analysis & Trends
Editas Medicine (EDIT) has reported Income from Continuing Operations for 11 consecutive years, with 25116000.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Income from Continuing Operations rose 59.58% year-over-year to 25116000.0; the TTM figure through Sep 2025 stood at 201526000.0 (up 7.44% YoY), while the FY2024 annual figure was 626090000.0, down 30.37% from the prior year.
- Income from Continuing Operations rose to 25116000.0 in Q3 2025 per EDIT's latest filing, from 51962000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 22185000.0 in Q4 2023 and bottomed at 4005050000.0 in Q1 2022.
- Historically, Income from Continuing Operations has averaged 444066263.16 across 5 years, with a median of 67606000.0 in 2024.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations sank 3901.13% — and 2023, when it soared 92.91%.
- Editas Medicine's Income from Continuing Operations stood at 33717000.0 in 2021, then sank by 71.62% to 57865000.0 in 2022, then soared by 61.66% to 22185000.0 in 2023, then sank by 105.52% to 45595000.0 in 2024, then surged by 44.92% to 25116000.0 in 2025.
- Business Quant data shows EDIT's Income from Continuing Operations at 25116000.0 in Q3 2025, 51962000.0 in Q2 2025, and 78853000.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Editas Medicine | 287.84 Mn | 141.19 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | -25.12 Mn |
| Jun 30, 2025 | -51.48 Mn |
| Mar 31, 2025 | -75.66 Mn |
| Dec 31, 2024 | -45.39 Mn |
| Sep 30, 2024 | -62.14 Mn |
| Jun 30, 2024 | -67.61 Mn |
| Mar 31, 2024 | -61.96 Mn |
| Dec 31, 2023 | -18.86 Mn |
| Sep 30, 2023 | -45.02 Mn |
| Jun 30, 2023 | -40.28 Mn |
| Mar 31, 2023 | -47.45 Mn |
| Dec 31, 2022 | -60.73 Mn |
| Sep 30, 2022 | -55.73 Mn |
| Jun 30, 2022 | -53.69 Mn |
| Mar 31, 2022 | -50.28 Mn |
| Dec 31, 2021 | -41.44 Mn |
| Sep 30, 2021 | -39.10 Mn |
| Jun 30, 2021 | -55.26 Mn |
| Mar 31, 2021 | -56.75 Mn |
| Dec 31, 2020 | -65.64 Mn |